<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660800</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-1020</org_study_id>
    <nct_id>NCT03660800</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects</brief_title>
  <official_title>An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy
      Subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101
      (Calcifediol) Extended-release Capsules in Japanese and non-Japanese Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">January 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs as assessed by industry standards</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of AEs will be summarized by arm for all treatment-emergent AEs. Number and percent of participants with AEs will be summarized by system organ class and preferred term and presented overall and by arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline of peak plasma concentration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Baseline finding will be measured against the different time points collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mean total of the different components of calcifediol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Descriptive statistics will be calculated for PD assessment in the per protocol population.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Vitamin D Insufficiency</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 450mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 1800mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 Capsules</intervention_name>
    <description>Calcifediol Extended-Release Capsules</description>
    <arm_group_label>CTAP101 Capsules 1800mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 450mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants are eligible to be included in the study only if all of the following criteria
        apply:

          1. Signed the informed consent form as described in Appendix 3 which includes compliance
             with the requirements and restrictions listed in the informed consent form (ICF) and
             in this protocol

          2. Willing and able to comply with study instructions and to commit to all study days

          3. Man or woman, 18 to 55 years of age inclusive at the time of signing the informed
             consent form

          4. Overtly healthy as determined by medical evaluation including medical history,
             physical examination, clinical laboratory tests

          5. Body mass index (BMI) within 18.0 to 30.0 kg/m2 (inclusive) and body weight not less
             than 50 kg

          6. Blood pressure (after at least 2 minutes of rest) between 90 and 140 mmHg systolic,
             inclusive, and no higher than 90 mmHg diastolic.

          7. A 12-lead ECG consistent with normal cardiac conduction and function, including:

               -  Sinus rhythm

               -  Pulse rate between 40 and 100 beats per minute (bpm)

               -  QTc interval â‰¤450 milliseconds (QT interval corrected using Fridericia correction
                  method [QTcF]

               -  QRS interval of &lt;120 milliseconds

               -  PR interval &lt;200 milliseconds

               -  Morphology consistent with healthy cardiac conduction and function

          8. Must have negative tests for drugs of abuse at Screening and Day -2

          9. Must have a negative alcohol test at Screening and Day -2

         10. Must have adequate venous access in both arms, in the opinion of the Investigator

         11. Has a screening serum total 25-hydroxyvitamin D level between 10 and 40 ng/mL,
             inclusive

         12. If male, must agree to use contraception as detailed in Appendix 5 of this protocol
             during the treatment period and for at least 3 months after the last dose of study
             treatment and refrain from donating sperm during this period

         13. If female, be sterile (ie, at least 1 month post-surgical sterilization, confirmed
             nonsurgical sterilization or at least 6 months post-menopausal [as determined by
             follicle stimulating hormone (FSH) / estradiol testing]); or who are of childbearing
             potential but are abstinent, have a surgically sterile partner (ie, at least 6 months
             postvasectomy), or are using a copper intrauterine device or a combination of at least
             2 acceptable barrier methods such as condom + intravaginal spermicide, diaphragm +
             intravaginal spermicide, or cervical cap + intravaginal spermicide. Contraceptive
             medications (oral or by other routes) containing steroid hormones are not allowed.
             Women of childbearing potential must not be lactating and must have a negative
             pregnancy test at screening and Day -2, and agree to continue their accepted method of
             contraception throughout the study. See guidance on contraceptives in Appendix 5.
             Additional Inclusion Criteria for Japanese Participants Only

        1. Be first generation Japanese defined as:

          -  Born in Japan

          -  Has 2 Japanese biological parents and 4 Japanese biological grandparents

          -  Has lived outside of Japan for less than 5 years

          -  Has made no significant changes in lifestyle, including diet, since leaving Japan
             Additional Inclusion Criteria for non-Japanese Participants Only

               1. Not of Japanese or Asian descent

               2. Parents and grandparents not born in Japan or in any Asian countries Note:
                  Retesting of abnormal lab values that may lead to exclusion will be allowed once.

        Retesting will take place during an unscheduled visit during the screening phase.

        Exclusion Criteria:

        Participants are excluded from the study if any of the following criteria apply:

          1. Has taken a Vitamin D supplement within 28 days prior to dosing

          2. Has a medically confirmed history of kidney stones within the previous 2 years

          3. Has a urine calcium: creatinine ratio &gt; 0.2 at the Screening visit

          4. Has a known or suspected hypersensitivity to any of the constituents of the
             investigational products

          5. Has a history of or current clinically significant medical illness including but not
             limited to, cardiac arrhythmias or other cardiac disease; hematologic disease;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias); lipid
             abnormalities; significant pulmonary disease, including bronchospastic respiratory
             disease; diabetes mellitus; hepatic or renal insufficiency (creatinine clearance below
             60 mL/min); thyroid disease; neurologic or psychiatric disease; infection; or any
             other illness that the investigator considers should exclude the participant or that
             could interfere with the interpretation of the study results.

          6. Clinically significant abnormal values for hematology, clinical chemistry, or
             urinalysis at screening as deemed appropriate by the investigator

          7. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at
             screening as deemed appropriate by the investigator

          8. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests
             positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests
             positive for HBsAg or anti-HCV at Screening.

          9. Has received an investigational drug or used an invasive investigational medical
             device within 1 month or within a period less than 10 times the drug's half-life,
             whichever is longer, before Day 1.

         10. Has donated 1 unit (450 mL) or more of blood or plasma within 30 days of dosing

         11. Has an acute illness within 5 days prior to the first dose of study medication

         12. Has received any prescribed systemic or topical medication within 14 days of dosing,
             received a vaccination within 30 days of dosing, or taken any nonprescription systemic
             or topical medication or herbal preparation within 7 days of dosing (exception:
             occasional use of acetaminophen or ibuprofen at nonprescription doses).

         13. History of drug or alcohol use disorder according to Diagnostic and Statistical Manual
             of Mental Disorders (5th edition) criteria within 5 years before Screening or positive
             test result(s) for alcohol and/or drugs of abuse (including prescription drugs such as
             stimulants, opioids, and benzodiazepines) at Screening or at Admission on Day -2

         14. Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level &gt;1.5
             times the upper limit of normal (ULN), active liver disease or jaundice at Screening
             or Day -2

         15. Is considering or has preplanned surgery or procedures that would interfere with the
             conduct of the study

         16. Is an employee of the investigator or study site, with direct involvement in the
             proposed study or other studies under the direction of that investigator or study
             site, as well as family members of the employees or the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Mussallem</last_name>
    <role>Study Chair</role>
    <affiliation>WCCT Global, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

